Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06368167

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

A Phase II, Single-arm, Open-label, Multicenter Study on the Efficacy of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
105 (estimated)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma

Conditions

Interventions

TypeNameDescription
DRUGSHR2554SHR2554

Timeline

Start date
2024-04-01
Primary completion
2027-04-01
Completion
2027-04-01
First posted
2024-04-16
Last updated
2024-04-16

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06368167. Inclusion in this directory is not an endorsement.